



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: contact@samratpharmachem.in

February 14, 2020

To,
Department of Corporate Services,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Outcome of the Board Meeting of the Company held today

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, February 14, 2020, has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended 31st December, 2019 and year to date from 1st April, 2019 to 31st December, 2019; which is enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 18:00 hrs and concluded at 19:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Sandeep Prajapati
Company Secretary & Compliance Officer



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar - 393 002, Gujarat
Corp Office : 701/702, Business Square, M. A. Road, Andheri (West), Mumbai - 400 058.
CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 31 December, 2019

(Rs. In Lakhs)

Particulars	Quarter ended			Year to date ended		Previous Year Ended
	31-Dec-19	30-Sep-19	31-Dec-18	31-Dec-19	31-Dec-18	31-Mar-19
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 (a). Net Income from Sales / Services	3,515.56	3,653.82	2,737.47	10,717.44	7,470.76	11,113.64
(b). Other Operating Income	3.53	41.87	3.93	49.48	28.05	45.67
Total Income	3,519.09	3,695.69	2,741.40	10,766.92	7,498.81	11,159.31
2. Expenditure						
a) Cost of materials consumed	3,724.41	3,300.90	2,438.17	10,237.85	7,132.70	10,353.24
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	(419.09)	29.85	99.86	(462.13)	(145.75)	(90.93)
d) Employee Costs	34.19	30.25	31.99	93.51	87.36	138.36
e) Interest	25.02	22.73	26.55	64.41	71.67	105.84
f) Depreciation & Amortisation expense	10.61	10.66	10.63	31.80	31.37	41.77
g) Other Expenses	91.74	86.24	96.60	279.43	275.26	395.27
Total	3,466.88	3,480.63	2,703.80	10,244.87	7,452.61	10,943.55
3. Profit before exceptional & extraordinary items & tax	52.21	215.06	37.60	522.05	46.20	215.76
4. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5. Profit before extraordinary items & tax	52.21	215.06	37.60	522.05	46.20	215.76
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
7. Profit before tax	52.21	215.06	37.60	522.05	46.20	215.76
8. Tax expense						
a) Current Tax	(11.07)	(52.51)	(7.80)	(127.38)	(8.06)	(61.46)
b) Deferred Tax	5.97	(12.29)	(1.47)	(10.31)	(14.67)	(0.75)
Total Tax Expense	(5.10)	(64.80)	(9.27)	(137.69)	(22.73)	(62.21)
9. Profit (Loss) for the period after tax	47.11	150.26	28.33	384.36	23.47	153.55
10. Other Comprehensive Income (OCI)						
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	47.11	150.26	28.33	384.36	23.47	153.55
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
13. Earnings per equity share						
a) Basic	1.52	4.86	0.92	12.44	0.76	4.97
b) Diluted	1.52	4.86	0.92	12.44	0.76	4.97

Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 31 December, 2019.
- The above results have been taken on record by the Board of Directors at its Meeting held on Friday, 14 February 2020 at the Corporate Office of the Company.
- The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 31 December 2019 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
- A principal amount of Rs. 8,20,837.50 is kept as contingent as the company is yet to receive the amount which is overdue from a debtor as on date.
- The Company manufactures pharmaceutical chemicals, which is a single business segment.
- Figures for the previous period have been regrouped / reclassified, wherever necessary.

By order of the Board of Directors
For Samrat Pharmachem Limited


Rajesh Mehta
Director

Place : Mumbai
Date : 14 February 2020





Independent Auditor's Report on Limited Review of the Unaudited Quarterly/ Year to Date Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

**To Board of Directors
Samrat Pharmachem Limited**


1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 31st December, 2019 and year to date from 1st April, 2019 to 31st December, 2019 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financials statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder other accounting policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

UDIN : 20108135AAAAAM7035

For SHAH & SAVLA LLP

Chartered Accountants

Firm Reg: No:109364W/W100143


CA. Miral H. Nagda
(Partner)

Membership No. 108135

Place: Mumbai

Date: 14 FEB 2020

